Drug Trial Radar · NCT07158151
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Sep 25, 2025
Primary completion
Apr 10, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis
Conditions
- Atopic Dermatitis of Adults
Interventions
RSS0393 ointmentDrug
RSS0393 ointment 0.05%
RSS0393 ointmentDrug
RSS0393 ointment 0.01%
RSS0393 ointmentDrug
RSS0393 ointment 0.03%
RSS0393 ointmentDrug
RSS0393 ointment placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with vIGA-AD successTime frame: Baseline, week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.